What are the adverse effects of torsemide?

Side Effects of Torsemide

Torsemide causes common diuretic-related adverse effects including electrolyte abnormalities (hypokalemia, hyponatremia, hypomagnesemia), volume depletion with hypotension, worsening renal function, and metabolic disturbances (hyperglycemia, hyperuricemia), with the most clinically significant being acute kidney injury and excessive urination. 1

Common Adverse Effects

Electrolyte and Metabolic Disturbances

• Hypokalemia occurs in a dose-dependent manner, with approximately 1.5% of patients on 5-10 mg daily developing serum potassium <3.5 mEq/L in hypertension trials, though this increases at higher doses used for heart failure, hepatic cirrhosis, or renal disease 1
• Hyponatremia, hypomagnesemia, hypocalcemia, and hypochloremic alkalosis can all occur and may be symptomatic 1
• Hyperglycemia develops with mean increases of 5.5 mg/dL after 6 weeks at 10 mg daily, though diabetic patients showed no significant changes in fasting glucose with long-term use 1
• Hyperuricemia is common (mean increase of 1.2 mg/dL at 10 mg daily), and gout may rarely be precipitated 1

Renal Effects

• Acute kidney injury represents a significant safety concern, with recent large-scale data showing torsemide associated with a 12% increased risk compared to furosemide (HR 1.12,95% CI 1.10-1.15) 2
• Worsening renal function can occur, particularly with excessive diuresis causing dehydration and blood volume reduction, especially in salt-depleted patients or those on renin-angiotensin-aldosterone inhibitors 1
• Small dose-related increases in BUN (mean 1.8 mg/dL) and creatinine (mean 0.05 mg/dL) occur at 10 mg daily, which reverse upon discontinuation 1

Volume-Related Effects

• Excessive urination occurred in 6.7% of patients in US trials (versus 2.2% on placebo), with dose-related frequency: 4% at 5 mg daily and 15% at 10 mg daily in hypertension studies 1
• Hypotension and symptomatic dehydration can result from excessive diuresis, particularly in volume-depleted states 1
• Hypovolemia showed no significant difference compared to furosemide in real-world data (HR 1.03,95% CI 0.98-1.09) 2

Serious but Less Common Adverse Effects

Ototoxicity

• Tinnitus and hearing loss (usually reversible) have been observed, with higher risk at doses exceeding recommendations, in severe renal impairment, and with hypoproteinemia 1
• Notably, no evidence of ototoxicity has been demonstrated in human studies at therapeutic doses 3

Dermatologic Reactions

• Stevens-Johnson syndrome and toxic epidermal necrolysis are rare but serious cutaneous reactions 1
• Photosensitivity reactions including photosensitive lichenoid reactions have been documented, likely representing photoallergic cell-mediated hypersensitivity 1, 4
• Pruritus can occur 1

Gastrointestinal Effects

• Pancreatitis is a rare but serious adverse effect 1
• Abdominal pain and diarrhea led to discontinuation in some patients 1, 5

Hematologic Effects

• Leucopenia, thrombocytopenia, and anemia have been reported in post-marketing surveillance 1

Hepatobiliary Effects

• Increases in liver transaminases and gamma-glutamyltransferase can occur 1

Neurologic Effects

• Paresthesia, confusion, visual impairment, and loss of appetite have been reported 1
• Dizziness and headache are common, along with fatigue 6

Other Effects

• Thiamine (vitamin B1) deficiency can develop with chronic use 1
• Acute urinary retention has been reported, and nocturia occurred in 4 patients taking bedtime dosing in one study 1, 5

Clinical Context and Monitoring

The overall discontinuation rate due to adverse reactions is low (3.5% versus 4.4% on placebo in US trials), indicating generally good tolerability 1. However, periodic monitoring of volume status, renal function, serum electrolytes, and blood glucose is essential 1. The risk-benefit profile must be carefully considered, particularly the increased acute kidney injury risk balanced against potential cardiovascular benefits 2.